“Our entire clinical and preclinical development portfolio is progressing as planned,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Significantly, our Investigational New Drug application to the U.S. Food and Drug Administration for ART26.12, our lead Fatty Acid Binding Protein 5 inhibitor for the treatment of neuropathic pain, is in the final stages of preparation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
- Artelo Biosciences announces publication of peer-reviewed article on FABP7
- Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
- Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Questions or Comments about the article? Write to editor@tipranks.com